Overview: Anti-IgLON-5 IgG TestIntroduction: The Anti-IgLON-5 IgG Test detects antibodies linked to neurological disorders, which may cause sleep problems, movement issues, or cognitive changes. Following 2023 AAN guidelines, it uses an immunoassay for high specificity, aiding in autoimmune screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected autoimmune neurological disorders.
Other Names: Anti-IgLON-5 Assay, IgLON-5 Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Autoimmune neurology testing advanced in the 2000s with antibody discovery. Anti-IgLON-5 assays emerged in the 2010s, and by the 2020s, immunoassays improved detection of rare neurological disorders.
Purpose: Diagnoses autoimmune neurological disorders, guides treatment, and monitors disease activity in patients with sleep problems, movement issues, or cognitive changes.
Test Parameters: 1. Anti IgLON-5 IgG
Pretest Condition: No fasting required. Collect serum, CSF, or saliva at any time. Report symptoms like sleep issues or cognitive changes, and list medications like immunosuppressants.
Specimen: 2-5 mL serum (SST), 1-2 mL CSF (sterile container), or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document neurological symptoms, autoimmune disease history, or family history of neurological disorders. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for immunosuppressive therapy or imaging.
Procedural Considerations: Uses an immunoassay to measure anti-IgLON-5 IgG antibodies. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Immunosuppressants may suppress antibody levels, causing false negatives. Hemolysis or improper storage can degrade samples.
Clinical Significance: Positive results confirm autoimmune neurological disorders, prompting immunosuppressive therapy. Negative results may require other antibody tests.
Specialist Consultation: Consult a neurologist for result interpretation. An autoimmune neurologist referral is advised for complex cases.
Additional Supporting Tests: Anti-NMDA antibody test, brain MRI, or CSF analysis to confirm autoimmune neurological disorders or assess disease extent.
Test Limitations: False negatives may occur with early disease or immunosuppressive therapy. Rare disorders require clinical correlation.
References: AAN Autoimmune Neurology Guidelines, 2023; Neurology, Dalmau J, 2022.
